Bugworks Research, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2014-02-04
- Employees
- 11
- Market Cap
- -
The Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of BWC0977 in Healthy Adult Volunteers
Phase 1
Terminated
- Conditions
- Bacterial InfectionsInfectious Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Bugworks Research Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT05942820
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Bacterial InfectionsInfectious Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Bugworks Research Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT05088421
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
© Copyright 2025. All Rights Reserved by MedPath